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Background: Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human
papillomaviruses (HPV), has been offered to 11–14 year-old schoolgirls in Switzerland since 2008. To evaluate its
success and its potential impact on cervical cancer screening, HPV genotypes were examined in 18-year-old girls
five years later (sub-study 1) and in outpatients participating to cervical cancer screening before and after vaccine
implementation (sub-study 2).
Methods: For sub-study 1, 3726 females aged 18 in 2013 were invited to fill a questionnaire on personal
demographics and HPV risk factors and to provide a self-collected cervicovaginal sample for HPV genotyping and
Chlamydia trachomatis PCR. Personal data were evaluated by univariable and multivariable statistics. In sub-study 2,
the proportion of the vaccine-type HPV among anogenital HPV was examined with archived genotyping data of
8039 outpatients participating to cervical cancer screening from 1999 till 2015. The yearly evolution of this
proportion was evaluated by segmented logistic regression.
Results: 690 (18.5%) women participated to sub-study 1 and 327 (8.8%) provided a self-collected sample.
Prevalence of Chlamydia trachomatis (4.6%) and demographics confirmed that the subjects were representative of
sexually-active Swiss young women. Vaccine (five-year coverage: 77.5%) was preferentially accepted by
contraceptive-pill users (P = 0.001) and samples were mainly provided by sexually-active subjects (P < 0.001). The
proportion (4%) of the vaccine-type HPV in this population was lower than in sub-study 2 outpatients (n = 849,
<26 years old) in the pre-vaccine era (25.7%). The proportion of the high-risk vaccine-type HPV decreased
significantly (59%, P = 0.0048) in the outpatients during the post-vaccine era, yet this decrease was restricted to
those aged less than 26 years (n = 673, P < 0.0001).
Conclusions: The low proportion of vaccine-type HPV in 18-year-old females and its rapid decrease in young
women participating to cervical cancer screening extend the success of HPV vaccination to Switzerland. Our data
suggest that cervical cancer screening is now entering a stage of reduced proportion of HPV16 and/or 18 in
samples reported positive by cytology. In view of the high likelihood of reduced clinical specificity of cytology,
primary screening modalities involving HPV testing and cytology should now be re-evaluated in Switzerland.
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Infection by high-risk (HR) anogenital human papillo-
maviruses (HPV) is a necessary cause of cervical cancer
(CC) [1]. HPV16 and 18 account for 70% of cases world-
wide, while the prototypic low-risk (LR) types, HPV6
and 11, cause the most frequent sexually-transmitted in-
fection (condylomata acuminata). Acquisition of ano-
genital HPV is associated with sexual debut [2]. Most
infections resolve within 2 years in immunocompetent
individuals, and less than 1 % of initial HR HPV infec-
tions can progress to CC over an extended period of
time (10–20 years) [3–5].
Vaccination against HR HPV targeting girls prior to
sexual debut is expected to reduce CC burden, even in
those who are not vaccinated thanks to herd immunity
[6]. Three HPV vaccines are currently available:
Cervarix® targeting HPV16 and 18, Gardasil® targeting
HPV6, 11, 16, and 18, and Gardasil-9® targeting HPV6,
11, 16, 18, 31, 33, 45, 52, and 58. Cervarix® and Gardasil®
could prevent 70% of CC cases and Gardasil-9® almost
90%. Proving HPV vaccines’ effectiveness against CC is
difficult owing to the long delay between initial infection
and cancer. Surrogate markers therefore have been pro-
posed to determine vaccines’ effectiveness on a shorter
term, such as population-based continuous monitoring
of high grade precursor lesions (cervical intraepithelial
lesions grade 3 or more, CIN3+) [7]. Accordingly, a
CIN3+ obligatory reporting system is being evaluated for
HPV vaccine monitoring in Switzerland [8].
Data obtained from large cohorts of women several
years after implementation of Cervarix® [9, 10] or
Gardasil® (reviewed by Garland et al. [11]) have shown
that both vaccines are efficient at reducing the frequency
of precursor lesions associated with the vaccine geno-
types. However, even the nonavalent vaccine will not be
able to prevent all CC cases, and a large fraction of older
women are presently not vaccinated. Successful preven-
tion of CC therefore will still rely on screening for years
to come. Cervical cancer screening modalities will need
to take into consideration the progressive reduction of
abnormal lesions harbouring the most carcinogenic
HPV genotypes. This reduction is expected to affect
negatively the clinical specificity of cytology [12]. The
knowledge of HPV burden in the transition from the
pre-vaccine to the vaccine era therefore is important in
countries such as Switzerland where cytology is used for
primary screening and HPV testing as an adjunct in an
opportunistic setting.
Gardasil® has been used in Switzerland and offered to
schoolgirls aged 11–14 since 2008, yet its impact is not
known in Switzerland. The aims of our work were to
examine the proportion of vaccine-type HPV among ano-
genital HPV in sexually-active 18-year-old Swiss females
five years after vaccine implementation, and the temporalimpact of Gardasil® on this proportion in outpatients par-
ticipating to CC screening from 1999 to 2015.
Methods
Study design
This is an observational study divided into two sub-
studies aimed at evaluating the distribution of HPV ge-
notypes within two sets of individuals in the context of
Gardasil® implementation in Switzerland.
Sub-study 1 comprised 18-year-old females (n = 3726)
invited through an independent marketing organization
(BVA Logistique SA, Le Mont-sur-Lausanne, Switzerland)
to participate in our study in 2013. BVA gets the residents’
records from all residents’ registration offices of the can-
ton of Vaud. Sub-study-1 individuals corresponded to
82.2% of the 18-year-old women officially registered in the
canton of Vaud as of December 31st 2013 (n = 4537, per-
sonal communication: Mabillard, H, October 2016, canton
of Vaud Statistical Office) since residents can oppose their
being included in the BVA database. Women of that age
had all been targeted by the vaccination campaign initi-
ated in 2008 when they were 13 years old, and could have
accepted the vaccine within this five-year period because
of catch-up vaccination that was offered to older girls aged
up to 19. This group served to establish the proportion of
vaccine-type HPV among anogenital-HPV in sexually-
active young women, up to five years after having been of-
fered HPV vaccination. It served also to establish the
demographics and uptake of vaccination in young women
in our canton to assess whether our findings can be gener-
alized to Switzerland. They were sent a questionnaire by
BVA to address (1) personal data, (2) preventive aspects
pertaining to HPV infection and cervical cancer and (3)
risk factors of HPV acquisition and of sexually transmitted
infections (STI) (Additional file 1). The questionnaire
served also for informed consent to provide a cervicovagi-
nal sample for HPV genotyping and Chlamydia trachoma-
tis (CT) testing, in which case women were sent a self-
collection device to their home address that was encoded
by BVA to ensure anonymity. CT prevalence was deter-
mined to evaluate the risk of STI independently of HPV
vaccine acceptance because it had previously been
assessed in sexually-active young women of the canton of
Vaud to be used here as a comparator [13]. Vaud (n =
773′000 inhabitants) is one of 26 cantons of Switzerland
(n = 8′327’000) and ranks third in terms of population
after Zürich (n = 1′466’000) and Bern (n = 1′017’000). No
financial incentive was used to encourage participation in
the study. However free CT consultation was offered to
those who were CT-positive provided they accepted to be
contacted.
Sub-study 2 comprised all outpatients (n = 8039) who
visited the clinics of the Gynaecology and Obstetrics
Service of our hospital centre and affiliated family
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Sub-study 2 served to assess the evolution of the propor-
tion of vaccine-type HPV encountered in screened
women before (1999–2007) and after the introduction of
HPV vaccination until 2015. HPV-genotype distribution
was retrospectively assessed with archived genotyping
data from a total of 12′706 samples submitted to our la-
boratory as an adjunct to abnormal cytology (n = 11′
576) or as follow-up (FUP, n = 1′130) after Papanicolaou
(PAP) testing. Abnormal cytology were atypical cells of
undetermined significance (ASCUS, n = 6′983), low
grade squamous intraepithelial lesions (LSIL, n = 4′423),
and high grade squamous intraepithelial lesions (HSIL,
n = 170). HPV testing of FUP samples was requested
despite normal cytology for patients who presented pre-
viously with persistent ASCUS or to monitor treatment.
HPV genotyping and CT real time PCR
Cervicovaginal sample (5 mL) was self-collected by sub-
study-1 individuals with the Delphi Screener® device
(Delphi Bioscience, BV Scherpenzeel, the Netherlands)
and transferred in a coded tube prior to sending to our
laboratory within 24 h. DNA from 200 μL cell suspen-
sion was isolated with the MagNaPure 96 Total Nucleic
Acids kit according to the manufacturer (Roche, Basel,
Switzerland) and eluted in 100 μL elution buffer. Five μL
was used for CT detection by real time PCR [14] and for
genotyping of 28 HPV genotypes (6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 42–45, 51–54, 56, 58, 59, 61, 66, 68–70,
73, and 82) by the Anyplex™ II HPV28 kit and the
HPV51 RUO kit according to the manufacturer
(Seegene, Seoul, South Korea). The HPV51 RUO kit was
used for HPV51, which is otherwise not well covered
with the Anyplex™ II HPV28 kit [15]. HPV- or CT-nega-
tive tests were valid only if their internal positive control
was positive (human DNA target and spiked internal
control, respectively). Negative controls were tested in
parallel throughout the procedures to monitor
contaminations.
DNA extraction and HPV genotyping (PGMY-CHUV
assay) for sub-study-2 individuals have been described
[16, 17].
Statistical analyses
Sub-study-1 questionnaires were reviewed to identify in-
consistent responses. Together with empty fields, they
were considered non informative (NI) and excluded
from statistical analysis (Additional file 1). A final table
was generated from the curated questionnaires and the
microbiological data. Fisher’s tests have been used to
highlight risk factors associated with HPV and CT infec-
tions. Multivariable logistic regression was used to inves-
tigate factors associated with vaccine acceptance and
with self-sampling acceptance.Sub-study-2 individuals were stratified in three age
groups (< 26, 26–30, and >30) to chart the yearly pro-
portion of the vaccine-type HPV among anogenital
HPV. This proportion was expected to diminish in the
youngest outpatients some year after vaccine introduc-
tion in 2008, and its evolution was analysed by seg-
mented logistic regression according to the following
model: logit(p) = b0 + b1 * year + b2 * max(year − A, 0),
where p is the proportion of the vaccine HPV types
among anogenital HPV and A is the breakpoint year at
which the regression coefficient changed. The model be-
fore the breakpoint year A is logit(p) = b0 + b1 * year
and the model after the breakpoint year A is logit(p)
= (b0 − b2 * A) + (b1 + b2) * year. Hence the odds ratio
associated with the yearly evolution of p before the
breakpoint is exp(b1) while the odds ratio after the
breakpoint is exp(b1 + b2) = exp(b1) * exp(b2). The value
exp(b2) is the multiplicative coefficient at the break-
point; it is a measure of the change in the odds ratio. A
coefficient significantly different from 1 is indicative of a
significant variation in the yearly evolution of p.
The age limit of 26 was based on the assumption that
the majority of vaccinated women would be younger
than 26, seven years after vaccine implementation, tak-
ing into account catch-up vaccination offered to women
aged up to 19. Genotypes were stratified by year of sam-
ple collection and patient’s age. For each patient, only
the first occurrence of a genotype was considered to
avoid overrepresentation of persistent viruses and to en-
rich the dataset in incident infections. Analysis was re-
stricted to the 26 anogenital HPV (6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 42, 44, 45, 51–54, 56, 58, 59, 66, 68–70,
73, and 82) shared between PGMY-CHUV and Anyplex™
II HPV28 to facilitate comparison with the genotyping
data of the 18-year-old sub-study-1 subjects. Version 1
of PGMY-CHUV was replaced mid 2013 by version 2 to
improve detection of HPV68a [17]. HPV68a therefore
was excluded from the calculation, which otherwise
would have had artificially diminished the proportion of
the four vaccine-type HPV from 2013 on.
Statistical analyses were performed with R version
3.2.3 [18] and GraphPad Prism (GraphPad Software, La
Jolla, CA) using a significance level of 0.05. P-values
were double-sided. Raw data and R script are available
as Additional files 2 and 3, respectively.
Results
Of 3726 sub-study-1 females, 690 (18.5%) responded to
the questionnaire (Additional file 1). Most subjects re-
ported being in good health condition (98.6%), using the
contraceptive pill (64%) and being student or in appren-
ticeship (88.8%). The five-year vaccination coverage was
77.5%; 56.3% of the vaccinated subjects underwent the
full three doses regimen. PAP test was normal for the
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examined (42.5%). All variables linked to undergoing
sexual activity were associated with vaccine acceptance
by univariable analysis (not shown). Being user of
contraceptive pill (1.82, P = 0.001) and being in appren-
ticeship as opposed to the other two working status (stu-
dent or other) (1.56, P = 0.04) were associated with a
higher odds ratio by multivariable analysis (Table 1).
Most (n = 562; 81.4%) of the 690 subjects had an inter-
course at least once in the previous five years (mean age
at sexual debut of 16.0 ± 1.4 years, Additional file 1) and
less than 5 % reported sexual debut occurring before age
14. The number of sexual partners was one (n = 189;
33.6%), two to five (n = 240; 42.7%) and more than five
(n = 62; 11%). Usage of condom was systematic for 115
subjects (20.5%). The majority of subjects had not been
treated for STI (>95%), nine (1.3%) reported suffering
from an immune-related disease and 203 reported being
smokers (29.4%).
Five hundred and forty-nine (79.6%) subjects accepted
self-sampling for HPV and CT analyses. Acceptance was
found in association with “having sexual intercourse”
(P < 0.001) and “being smoker” (P = 0.02) by multivari-
able analysis (Additional file 4, panel A). However, only
327 (59.6%) eventually provided a self-collected sample
resulting in a low proportion (8.8%) of women among
the entire population to be examined for HPV and CT.
The working status “being student” was significantly as-
sociated with having actually provided a sample (P =
0.04) by multivariable analysis (Additional file 4, panel
B). The vast majority (99.7%) considered the self-
collection device user-friendly.
Of the 327 self-collected samples, 324 were inform-
ative for HPV and 327 for CT. The proportion of
subjects infected by any type of HPV was 29.5%
(2.8% for vaccine-type HPV only, Table 2). There
were 38 single infections and 57 multiple infections
with up to seven genotypes (average 3.1, not shown).
CT infection was used as a proxy for risk of STI in-
dependent of HPV vaccination. The prevalence of CT
infections was 4.6% (n = 15) and did not differ signifi-
cantly with the vaccinal status of the subjects (Table
2). As expected the majority of CT-positive cases
were found among HPV-positive women (13 CT-posi-
tive / 95 HPV-positive vs. 2 CT-positive / 229 HPV-
negative, Fisher’s P-value <0.001).Table 1 Factors associated with vaccine acceptance in sub-study-1
Vaccination status Negative (n = 152) Vac
Independent variable Number Proportion Nu
Contraceptive pill use Yes 80 0.53 361
Working status
Apprentice
36 0.24 179
CI Confidence intervalFactors associated with HPV acquisition were being
sexually active (P = 0.012) with a higher number of sex
partners (P < 0.001) (Table 3). Condom use (P = 0.03),
having been treated for an STI (P = 0.001), being exam-
ined with PAP (P = 0.001), and working status being nei-
ther a student nor an apprentice (P < 0.001) were also
significantly associated with HPV positivity in contrast
to tobacco smoking (P = 0.236). The working status was
also associated with CT positivity (P = 0.01, not shown).
The other univariable analyses for CT acquisition were
however inconclusive because of the low number of
positive cases.
The distribution of the 217 genotype-sample combina-
tions in 18-year-old sub-study-1 subjects in 2013 is
graphically displayed according to their vaccination sta-
tus in Fig. 1 a. The proportion of the four vaccine-type
HPV (n = 9) was 4% (9/217), with HPV16 (n = 6) rank-
ing 14th, HPV6 (n = 3) 20th, HPV11 and HPV18 (n = 0)
23rd.
The HPV genotype-sample combinations (n = 3619)
observed before vaccine implementation (1999–2007) in
the sub-study-2 outpatients were distributed by year and
patients’ age (<26, 26–30 and >30), and ranked by de-
creasing occurrences within the youngest age group
(<26, n = 1438 genotype-sample combinations) (Fig. 1
b). The proportion of the four vaccine-type HPV (n =
369) was 25.7%, with HPV16 (n = 212) ranking first,
HPV6 (n = 74) fifth together with HPV58, HPV18 (n =
64) 10th, and HPV11 (n = 19) 21st. Restricting the out-
patients’ population to the youngest age (<26) with nor-
mal cytology (n = 87; 50 HPV-negative) gave a similar
proportion (25%) (n = 14 out of 56 genotype-sample
combinations); HPV16 (n = 7) ranked first (data not
shown). To test whether this proportion decreased after
vaccine implementation, as suggested by the low propor-
tion observed in the sub-study-1 subjects, the yearly pro-
portion of the four vaccine-type HPV was calculated
from 1999 to 2015 for each of the three age groups of
outpatients, and its evolution examined by segmented
logistic regression. Model adjustment was made to
evaluate the year at which the regression coefficient of
the model changed (breakpoint year, Additional file 5).
No significant variation was observed for the patients
aged >25. In contrast, a significant reduction in the pro-
portion of the four vaccine-type HPV was observed for
the patients aged <26 starting in 2010, two years afterparticipants
cination status Positive (n = 535) Odds ratio
mber Proportion value 95% CI p-value
0.67 1.82 1.26 2.63 < 0.001
0.33 1.56 1.02 2.36 0.04
Table 2 HPV and CT prevalence among sub-study-1 subjects
Population
(CT n = 327, HPV n = 324)
Vaccinees
(CT n = 248, HPV n = 245)
Non vaccinees
(CT n = 77, HPV n = 77)
p-value
n pr sd n pr sd n pr sd
CT 15 4.6 1.2 10 4.0 1.3 5 6.5 2.8 0.360
HPV global 95a 29.5 2.5 70 28.6 2.9 25 32.5 5.4 0.567
HPV vaccine 9b 2.8 0.9 6 2.4 1.0 3 3.9 2.2 0.451
Of 327 samples analysed, 327 were informative for Chlamydia trachomatis (CT) and 324 for Human papillomaviruses (HPV)
Two subjects were non informative regarding their vaccine status. They were CT and HPV negative. The 15 CT positive cases were found in 13 HPV positive cases
and 2 HPV negative cases
n: number of positive subjects; pr: proportion in %; sd: standard deviation in %; p-value: two-sided Fishers’ p value
aIn total, 217 subject-genotype combinations were found in the 95 HPV positive subjects. Their distribution is shown in fig. 1
bFour subjects were infected by a single vaccine genotype. Five were infected by a single vaccine genotype and by at least another non vaccine genotype
Table 3 Factors affecting HPV positivity
HPV neg HPV pos Proportion of HPV pos in % Fisher test p-value
Sexually active
No 24 2 7.7 0.012
Yes 198 91 31.5
Number of sex partners
1 78 14 15.2 < 0.001
2–5 86 32 27.1
> 5 10 27 73.0
Tobacco smoking
No 163 61 27.2 0.236
Yes 66 34 34.0
PAP smear
No 133 37 21.8 0.001
Yes 92 57 38.3
Condom use
No 154 84 35.3 0.003
Yes 44 7 13.7
Contraceptive pill use
No 77 23 23.0 0.113
Yes 152 72 32.1
STI treatment
No 215 79 26.9 0.001
Yes 10 16 61.5
Health status: good
No 4 1 20.0 1.000
Yes 224 93 29.3
Working status
Student 148 40 21.3 < 0.001
Apprentice 64 33 34.0
Other 17 22 56.4
The sum of cases is not always equal to 324 because of non informative responses to the questionnaire, which have been excluded from analysis
Neg Negative, Pos Positive
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Fig. 1 a Distribution of HPV genotypes in 95 sub-study-1 18-year-old girls in 2013, five years after having been offered Gardasil®. Genotypes were
determined with the Anyplex™ II HPV28 kit and restricted to those shared with the PGMY-CHUV assay. The seven most prevalent genotypes by
decreasing occurrences among vaccinees and non vaccinees were HPV42, 51, 53, 66, 39, 52 and 59. Members of the Gardasil® vaccine ranked
14th (HPV16), 20th (HPV6) and 23rd (HPV11 and 18). Vaccine did not affect the repartition of either genotypes among the non-vaccinated and
vaccinated subjects (p > 0.05, not shown) although differences would be difficult to identify due to the low number of cases. The relatively high
prevalence of HPV42 may in part be due to a higher sensitivity of Anyplex™ II HPV28 compared with PGMY-CHUV for this genotype. HPV genotyping
with both assays is otherwise highly comparable [15]. b Distribution of HPV genotypes in 2272 HPV-positive sub-study-2 outpatients stratified in three
age-groups referred to HPV testing from 1999 till 2007. Genotypes were determined with the PGMY-CHUV assay and restricted to those shared with
the Anyplex™ II HPV28 kit. The seven most prevalent genotypes by decreasing occurrences among the youngest women (<26) were HPV16, 53, 51, 66,
58, 6, and 52. Members of the Gardasil® vaccine ranked first (HPV16), sixth (HPV6), 10th (HPV18) and 21st (HPV11)
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2009, OR = 0.82, P < 0.0001) (Fig. 2 and Additional file
5). The same analysis performed after further stratifying
the youngest age group (<21, 21–25) confirmed this re-
sult (OR = 0.73, P = 0.05 and OR = 0.77, P < 0.001, re-
spectively; Additional file 5). To establish the percentage
of reduction of the vaccine-type HPV, the average yearly
proportions of the vaccine-type HPV in the pre-vaccine
era (1999–2007) was compared with that in the post-
vaccine era at the plateau (2013–2015, fig. 2) for the
youngest outpatients (<26). It was 25.5% (95% CI:
20.8%–30.1%) in the pre-vaccine era and significantly re-
duced by 56% (P = 0.0028 unpaired t test) in the post-
vaccine era to 11.3% (95% CI: 10.2%–12.5%). Restricting
the vaccine genotypes to HPV16 and HPV18, excludingHPV6 and HPV11 from the calculations, gave similar re-
sults; average yearly proportions of 21.0% (95% CI:
16.6%–25.3%) compared with 8.7% (95% CI: 6.7%–
10.8%), 59% reduction (P = 0.0048).
Discussion
This study is the first to investigate the impact of Gardasil®
after its introduction in 2008 in Switzerland. We first
assessed vaccination coverage and demographics as well
as HPV genotypes in an 18-year-old women population
targeted by the vaccine five years earlier in the canton of
Vaud. The participation rate was low with 18.5% returned
questionnaires and 8.8% self-collected samples. The low
participation rate is a major weakness of this sub-study
that necessitated to verify the representativeness of the
Fig. 2 Segmented logistic regression of the yearly proportion of vaccine-type HPV in 3869 HPV-positive sub-study-2 outpatients from 1999 till
2015. Genotypes were determined with the PGMY-CHUV assay and corrected for HPV68a bias (see Methods), and restricted to those 26 shared
with the Anyplex™ II HPV28 kit. A significant (p < 0.001) reduction of the yearly proportion of the four vaccine-type HPV among shared HPV genotypes
is evident only in the outpatients aged <26 after the breakpoint year (2009). For the other age groups the breakpoint year was not associated with a
significant variation of the odds ratio (p > 0.2) (Additional file 5)
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comparable to the Swiss women population of similar age
based on risk factors for HPV such as hormonal contra-
ception and use of condoms (Swiss Federal Statistical Of-
fice) [19] and on demographics of adolescents in
Switzerland (SMASH-02 report) [20]. The education
levels of the participants were also comparable to the gen-
eral population of the same age in the canton of Vaud.
Thus the proportions of students (57.5% ± 3.7%) andsubjects without formation (11.1% ± 2.3%) overlapped
those of the 18-year-old population registered December
31st 2013 (53.1% ± 1.5%, 8.8% ± 0.8%, respectively) while
apprentices (31.3% ± 3.5% vs. 38.0% ± 1.4%, respectively)
were slightly underrepresented (personal communication:
Mabillard, H, October 2016, canton of Vaud Statistical Of-
fice). Vaccinees and non vaccinees showed similar rates of
CT infections, consistent with HPV vaccination not influ-
encing sexual behaviour as reported by others in England
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(4.6 ± 1.2%) was similar (5.5 ± 0.9%) to that of a previous
survey of sexually-active women aged <25 in the same area
of Switzerland [13], consistent with sexually-active subjects
having preferentially provided a self-collected sample.
In the canton of Vaud, 69.5% of the schoolgirls aged
14 have been vaccinated (≥1 dose) against HPV during
the 2010–2011 school year [23]. The vaccination rate re-
ported by the subjects in our study is somewhat higher
at 77.5%. This is most likely due to catch-up vaccination
offered to women aged up to 19. In contrast, only 56%
of the vaccinees reported having had the three-dose regi-
men compared with 96% in the 2010–2011 survey. This
difference most likely reflects some degree of unreliabil-
ity of the self-reported vaccination status (regimen in
particular). This mode of reporting was preferred to con-
sultation of vaccination books by nurses to minimize
costs and ensure anonymous treatment of the files ac-
cording to our ethical approval.
The percentages of women who systematically used
condoms (20.5%) and contraceptive pills (64%) are simi-
lar to those of young women in a stable relationship
(36.1% and 64%, respectively) (SMASH-02 report) [20].
This suggests that the majority was engaged in a stable
relationship at time of questionnaire, consistent with the
mean age at sexual debut (16.0 ± 1.4 years). This age is
similar to that reported in Germany and in other
European countries [24–26]. In addition, less than 5% of
girls from our study reported having initiated sexual
intercourse at 13 years or younger, in line with the rec-
ommended age (11–14) for vaccination in Switzerland.
A low percentage of returned samples (12%) was re-
ported in a German study assessing HPV prevalence in
women aged 20–25 years using the Delphi-Screener®
[24]. The even lower percentage (8.8%) in our study may
reflect consecutive shipment of questionnaire and self-
collection devices while it was simultaneous in the
German study. Self-sampling was accepted more fre-
quently by women having sexual intercourse, and those
actually providing a sample were more frequently stu-
dents. This latter observation may be related to a pos-
sibly better knowledge of HPV infection by women with
a higher level of education.
Global HPV prevalence increased with number of sex
partners and other variables linked to undergoing sexual
activity, as well as with lower degree of education. These
data confirm previously published data on identified risk
factors for HPV infection [4]. Four participants in the
sub-study-1 vaccinated group were positive for HPV16.
Three reported to have received the three recommended
doses, whereas one mentioned two doses. All four re-
ported being sexually active after the vaccination was
completed. The low response rate and the overall low
numbers of vaccine-type HPV-positive cases as well assome degree of unreliability of self-reporting did not
allow meaningful statistical evaluation of the age at vac-
cination and age at first sex to test the hypothesis that
HPV16-positive vaccinees may have been infected before
vaccination. Taking into account the information pro-
vided by the volunteers, the presence of HPV16 in vacci-
nees may also reflect transient infections or vaccine
failures that cannot be distinguished since HPV genotyp-
ing was performed at a single time point, thereby ex-
cluding assessment of persistent infections.
In view of the vaccination coverage well above 50%,
the low proportion (4%) of the vaccine-type HPV was
expected in our 18 year-old subject population com-
pared with that (25%) in the youngest sub-study-2 out-
patients during the pre-vaccination era according to a
recent meta-analysis of the impact of HPV vaccination
programmes and herd effect [6]. Herd immunity induced
by HPV vaccination is reported by more and more re-
searchers across the globe [11]. For instance, several
studies have shown a major decline in the prevalence of
vaccine-type HPV and in clinical expressions of HPV-
induced illnesses like genital warts in Australian boys be-
fore their access to HPV vaccination [27].
The lower proportion of the vaccine-type HPV in sub-
study-1 subjects may have resulted from using different
means of sample collection (Delphi screener self-
collection vs. PAP smear) and HPV genotyping assays
(Anyplex II™ HPV28 vs. PGMY-CHUV), hence for this
reason was not tested statistically. The strength of our
study however relied on our ability to assess without bias
the evolution of the yearly proportion of the vaccine-type
HPV with the sub-study-2 outpatients’ data because the
cervical cancer screening algorithm, sample collection and
HPV genotyping method remained identical over the years
(1999–2015). The youngest sub-study-2 outpatients (<26)
were most likely enriched in women to whom the vaccine
was offered since 2008, while the older women (26–30
and >30) were gradually less likely to have received the
vaccine or have benefitted from herd immunity. Consist-
ent with this and with the known clearance time of HPV
(90% within two years), a time wise significant reduction
of the yearly proportion of the four vaccine-type HPV was
observed for our outpatients aged <26. The 56% reduction
of the four vaccine-type HPV and the 59% reduction of
HPV16 and HPV18 achieved as of five years after vaccine
implementation is reminiscent of the numbers published
in the US [28] [29] and in the UK [30–32]. Our data add
to these studies the yearly kinetic of reduction of the
vaccine-type HPV in a real-world condition of opportunis-
tic cervical cancer screening. We could not establish the
prevalence of HPV genotypes in the global population
since the sub-study-2 population represented a high-risk
group of screened women referred to HPV testing based
on cervical abnormalities. Also, we could not evaluate
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portion of high grade lesions, population wise, as has been
published for Scotland, which shows a reduction in the
proportion of CIN lesions in vaccinees under an orga-
nized screening algorithm [33]. Our data will however
be useful to evaluate cervical cancer screening modal-
ities in the vaccine era in Switzerland and in other
countries with similar vaccination coverage and op-
portunistic screening algorithms.
Conclusions
The low proportion of vaccine-type HPV in 18-year-old
females and its rapid decrease in young women partici-
pating to cervical cancer screening extend the success of
HPV vaccination to Switzerland. Our data suggest that
cervical cancer screening is now entering a stage of de-
clining prevalence of precursor lesions associated with
the two most carcinogenic HPV as proposed earlier by a
modelisation study [34]. There is good evidence that the
decline of HPV16 and HPV18 will negatively affect the
clinical specificity of cytology but not that of high-risk
HPV testing [12] with a concomitant diminution of the
positive-predictive value of cytology [35]. Primary
screening modalities involving HPV testing and cytology
should now be re-evaluated in Switzerland.
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